
MDxHealth SA (MDXH) Stock Forecast & Price Target
MDxHealth SA (MDXH) Analyst Ratings
Bulls say
MDxHealth is experiencing some short-term challenges, particularly with the discontinuation of the Resolve UTI test and a CMS matter, but the company's long-term prospects remain strong. Their flagship Exosome test has strong commercial traction and the company has recently announced positive coverage determinations for this test. The company is actively defending against the CMS matter and has taken steps to reposition its sales strategy for sustained growth. Despite a near-term decrease in revenue and updated guidance, MDxHealth's focus on personalized cancer diagnosis and treatment solidifies a positive outlook for the company's future performance.
Bears say
MDxHealth is facing some challenges with its recent acquisition of Exact Sciences' Oncotype DX GPS test, as the company is seeing slower-than-expected growth and potential recoupment of payments from Novitas. Additionally, the recent discontinuation of its Resolve UTI test and lower-than-expected test volumes in its recent quarter are cause for concern. However, the company's potential for growth with its ExoDx test and focus on strategic acquisitions could provide some upside in the future.
This aggregate rating is based on analysts' research of MDxHealth SA and is not a guaranteed prediction by Public.com or investment advice.
MDxHealth SA (MDXH) Analyst Forecast & Price Prediction
Start investing in MDxHealth SA (MDXH)
Order type
Buy in
Order amount
Est. shares
0 shares